Owkin

Owkin applies federated learning and artificial intelligence to biomedical research, enabling pharmaceutical companies and academic medical centres to collaborate on sensitive patient data without that data ever leaving its source institution. Founded in 2016 and headquartered in New York, with significant operations in Paris, the company was built on the premise that the most clinically valuable datasets are also the most difficult to centralise, and that AI trained across distributed hospitals can outperform models trained on any single institution's records.

The company's core platform, OwkinConnect, allows research partners to train AI models across federated networks of hospitals and research centres spanning Europe and North America. This approach has been applied most extensively to oncology, where Owkin has worked with academic partners to develop tissue-based biomarkers and patient stratification tools using digital pathology and multi-omic data. The company has established partnerships with major pharmaceutical groups and leading cancer centres including MSK and UCSF.

Owkin operates at the intersection of software and drug discovery, licensing its AI-derived biomarkers and collaborating with biopharma partners on clinical trial design and patient selection. Its research outputs have been published in peer-reviewed journals, giving the platform academic as well as commercial credibility. The company has raised substantial venture funding from investors including Sanofi, which took a strategic stake, reflecting the pharmaceutical industry's appetite for federated AI capabilities.

Further information is available at owkin.com.